Dr. Davide Gianni got his PhD from the University of Naples “Federico II” in 2006 with a thesis on molecular mechanisms underlying the pathophysiology of Alzheimer’s disease. He continued his studies at the Scripps Research Institute (TSRI) in La Jolla California in the Department of Immunology and Microbial Sciences where his research was focussed on the identification of novel inhibitors for the NADPH oxidase-1 enzyme. Results from these studies have been published on several first authored publications and his work has been featured in News and Views and Editorial Perspective of Science Signaling.
In 2010 he moved to industry as a Research Laboratory Head at Boehringer-Ingelheim, Vienna where his focus has been the identification and validation of novel targets for oncology drug discovery. By mentoring PhD and non-PhD scientists including undergraduate students, he has led a number of drug discovery projects and collaborations with CRO and academic institutions. Results of these research efforts have also been published in peer-reviewed scientific journals while, in addition to this, he has authored several patent applications. In 2013, he was recognised with the 2013 Boehringer-Ingelheim Silver Award for his contribution to advancing the field of epigenetic drug discovery and bringing novel medicine to patients.
In 2015, Davide joined Astrazeneca in Cambridge UK where he currently holds a Team leader position, leading a team of highly qualified scientists to develop cellular assays for oncology and neuroscience.
Molecular and cellular biology; Target identification and validation; Assay development.